fluorothymidine Report issue

Small molecule Imaging Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Alovudine (fluorothymidine) is an antiviral agent which was being developed by Medivir. It was discontinued after a Phase II trial in 2005 due to toxicity. It is a DNA polymerase inhibitor.   Wikipedia

Chemistry

  • SMILES: Cc1cn([C@H]2C[C@H](F)[C@@H](CO)O2)c(=O)[nH]c1=O
  • InChIKey: UXCAQJAQSWSNPQ-XLPZGREQSA-N
  • Mol. Mass: 244.22
  • ALogP: -0.54
  • ChEMBL Molecule:
    alovudine  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Imaging: 18-fluoride
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

1-(3'-fluoro-3'-deoxy-beta-d-erythropentofuranosyl)thymine | (18f)3'-deoxy-3'-fluorothymidine | (18f)flt | 18f flt | 18f-flt | 18f-flt-tep | 18f fluorothymidine | 18f-fluorothymidine | (18)flt cpd | 3'-deoxy-3'-(18f)fluorothymidine | 3'-deoxy-3'-18f-fluorothymidine | [3'-deoxy-3'-[f-18] fluorothymidine | 3'-deoxy-3'-fluorothymidine | 3'-(f-18)fluoro-3'-deoxythymidine | 3'-fluoro-2',3'-dideoxythymidine | 3'-fluoro-3'-deoxythymidine | 3'-fluorothymidine | alovudine | cl-184824 | fddt | fluoro-l-thymidine | fluorothymidine | pet

Organizations (57)

Research & Development (57)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (46)

Approved Indications (1)


 

Positron-Emission Tomography

Experimental Indications - Clinical Trial Phases 1-4 (45)


 

Anus Neoplasms (Phase 2)

Astrocytoma (Phase 1/Phase 2)

Brain Neoplasms (Phase 2)

BRCA1 Protein (Phase 1)

Breast Neoplasms (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Carcinoma, Verrucous (Phase 1)

Diagnostic Imaging ()

Endometrial Neoplasms (Phase 2)

Genital Neoplasms, Female (Early Phase 1)

Glioblastoma (Phase 1/Phase 2)

Glioma (Phase 1/Phase 2)

Graft vs Host Disease (Early Phase 1)

Head and Neck Neoplasms (Phase 2/Phase 3)

HIV Infections (Phase 2)

Laryngeal Neoplasms (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1/Phase 2)

Melanoma (Phase 2)

Mouth Neoplasms (Phase 2)

Mutation (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neurofibromatoses (Phase 1)

Neurofibrosarcoma (Phase 1)

Oropharyngeal Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Prostatic Neoplasms (Phase 2)

Rectal Neoplasms (Phase 2)

Salivary Gland Neoplasms (Phase 1)

Sarcoma (Early Phase 1)

Sarcoma, Ewing (Phase 1)

Stomach Neoplasms (Phase 2)

Thymus Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Uterine Neoplasms (Phase 2)

Vaginal Neoplasms (Phase 2)

Vulvar Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 73
  • # of Trial Organizations: 57

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue